Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPP5A | Q14642 | 2/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31470602 | 0.88 | INPP5A (0.41) | INPP5ASCN1ASCN2ASCN3AMEN1 | |
| SCHEMBL22479228 | 0.88 | INPP5A (0.41) | INPP5ASCN1ASCN2ASCN3AMEN1 | |
| SCHEMBL2238965 | 0.78 | — | — | |
| SCHEMBL681678 | 0.78 | HRH3 (0.41) | INPP5ACYP2D6 | |
| SCHEMBL10241703 | 0.78 | SMN1; SMN2 (0.44) | INPP5AMEN1KMT2ACHRM3MAPT | |
| SCHEMBL24407723 | 0.78 | INPP5A (0.40) | INPP5ASMPD1 | |
| SCHEMBL25547642 | 0.78 | INPP5A (0.40) | INPP5ASMPD1 | |
| SCHEMBL13602505 | 0.78 | INPP5A (0.40) | INPP5AALDH1A1SMN1; SMN2 | |
| SCHEMBL2760287 | 0.77 | INPP5A (0.42) | INPP5ACHRM3CHRM4SMPD1 | |
| SCHEMBL14565210 | 0.76 | SMN1; SMN2 (0.49) | INPP5AMEN1KMT2ACHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020194160-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS | LUPIN LIMITED (IN) | 2020-10-01 | — | — | WO | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| EP-1575966-B1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1800684-A1 | Novel alkyl phospholipid derivatives and uses thereof | Zentaris GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | INPP5A 1171/4885SCN1A 4680/4885SCN2A 4550/4885 |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | RICTOR, MTOR, RPTOR | INPP5A 3465/4885SCN1A 3934/4885SCN2A 3497/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | INPP5A 2491/4885SCN1A 4422/4885SCN2A 4115/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | INPP5A 2073/4885SCN1A 4678/4885SCN2A 4462/4885 |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | INPP5A 2338/4885SCN1A 4023/4885SCN2A 3972/4885 |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, AURKA, AURKB | INPP5A 2644/4885SCN1A 3048/4885SCN2A 3149/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | INPP5A 824/4885SCN1A 2684/4885SCN2A 2677/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | INPP5A 2521/4885SCN1A 2544/4885SCN2A 2942/4885 |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | MPL, MTX2, SLC10A1 | INPP5A 2521/4885SCN1A 2544/4885SCN2A 2942/4885 |
| US-20100179145-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, CDK6 | INPP5A 3452/4885SCN1A 2026/4885SCN2A 2427/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | INPP5A 2080/4885SCN1A 3023/4885SCN2A 3459/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | INPP5A 1050/4885SCN1A 2760/4885SCN2A 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.